Changes in CMRF during the intervention
At the end of the period, a significant improvement in CMRF was observed
across the total sample with changes in mean weight (- 0.8 Kg,
p<0.001), BMI (- 0.3 Kg/m2,
p<0.001), SBP (- 1.4 mmHg, p=0.01), DBP (- 0.9 mmHg, p=0.01),
though changes in the number of CMRF were not significant (- 0.04,
p=0.16). The positive changes were present in the MDT group, weight
(-1.4 Kg, p<0.001), BMI (-0.5 Kg/m2, p<0.001), SBP
(-1.5 mmHg, p=0.01), DBP (-1.1 mmHg, p=0.01) with a reduction of the
number of CMRF (-0.1, p<0.001). By contrast, no changes were
observed in the PCP group other than an increase in the number of CMRF
(+0.1, p=0.02) (Table 2). Sixty-one percent of patients (n=364) had a
baseline reading for A1c in Q1; among them, 137 (37.6%) had a baseline
A1c at or above 6.5%. MDT co-management was activated in 97% of these
patients (n=133). Due to the small number of patients in the PCP group
meeting this criterion, between-group changes in A1c were not assessed.
As compared with baseline A1c, the MDT group experienced sustained and
significant reduction in A1c values, (ΔA1c reading 2 & 1 = -0.52
[-0.89, -0.15] p =0.01, n=132; ΔA1c reading 3 & 1 = -0.49 (-0.91,
-0.06), p =0.03, n=122). Changes between reading 4 and 1 kept a similar
trend, though significance was lost (ΔA1C reading 4 & 1 = - 0.32 (-
0.80, - 0.15), p = 0.18, n=88).